More Americans received at least 1 dose of Covid vaccine than tested positive

More Americans received at least one dose of the Covid-19 vaccine than tested positive for the virus, an early but promising milestone in the race to end the pandemic.

As of Monday afternoon, 26.5 million Americans had received one or both doses of current vaccines, according to data compiled by the Bloomberg Vaccine Tracker. Since the first US patient tested positive outside Seattle a year ago, 26.3 million people in the country tested positive for the disease and 443,000 died, according to data from Johns Hopkins University.

The United States has administered injections at a faster daily rate than any country in the world, giving about 1.34 million doses a day, according to data collected by Bloomberg. Although the launch stumbled in its early days, in the six weeks since the first vaccines came into combat, almost 7.8% of Americans received one or more doses and 1.8% are fully vaccinated.

“It is important to note that today, for the first time, the data indicates that more people have been vaccinated than reported as newly diagnosed cases,” said Paula Cannon, professor of microbiology at the Keck School of Medicine at the University of Southern California. “It is worth celebrating. I am totally in favor of this victory. “

covid-vaccine-tracker-global-distribution-online

Only a few other countries have passed this milestone: Israel, the United Kingdom and the United Arab Emirates beat the United States in the queue for more vaccines than cases days or weeks ago.

After a wave of holidays in American cases, staff at the Center for Disease Control and Prevention are calling the top, although this is likely due to behavioral changes and not yet to the widespread impact of the vaccine. Cases, hospitalizations and visits to the new Covid-19’s emergency department are starting to decline, said Jay Butler, deputy director of the infectious disease agency.

“While these trends are encouraging, I want to emphasize that the national numbers are still high and are as high as at any time in the pandemic up until at this point, ”he said at a meeting on Friday organized by the Infectious Diseases Society of America. “If this pandemic were a stock, we might want to sell.”

It is still possible that the virus will roar again, especially if the variants that are emerging in South Africa and elsewhere are established. Studies suggest that vaccines, particularly the latest vaccines from Johnson & Johnson and Novavax Inc., are less potent against this strain and at least one other.

.Source